Clovis Oncology, Inc. (NASDAQ:CLVS) marched up 128.52% compared to a 52-week low price of $11.5. The shares were last seen trading -4.37% lower, taking the closing price at $26.28 on 3/19/2019. At a recent session, the prices were hovering between $26.24 and $27.5. This company shares are 23.67% off its target price of $32.5 and the current market capitalization stands at $1.39B. The recent change has given its price a 3.42% lead over SMA 50 and -59.72% deficit over its 52-week high. The stock witnessed 3.1% gains, 26.59% gains and -17.28% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CLVS’s volatility during a week at 4% and during a month it has been found around 6.41%.Clovis Oncology, Inc. (CLVS) Top Holders
Institutional investors currently hold around $1.47 billion or 0% in CLVS stock. Look at its top three institutional owners: Palo Alto Investors Lp owns $143.98 million in Clovis Oncology, Inc., which represents roughly 10.36% of the company’s market cap and approximately 9.79% of the institutional ownership. Similar statistics are true for the second largest owner, Armistice Capital, Llc, which owns 5,036,000 shares of the stock are valued at $138.39 million. The third largest holder is Vanguard Group Inc, which currently holds $125.33 million worth of this stock and that ownership represents nearly 9.02% of its market capitalization.
At the end of December reporting period, 93 institutional holders increased their position in Clovis Oncology, Inc. (NASDAQ:CLVS) by some 14,816,997 shares, 109 decreased positions by 16,835,261 and 21 held positions by 21,833,189. That puts total institutional holdings at 53,485,447 shares, according to SEC filings. The stock grabbed 28 new institutional investments totaling 3,601,896 shares while 53 institutional investors sold out their entire positions totaling 9,690,869 shares.Clovis Oncology, Inc. (CLVS) Analyst Guide
Several analysts have released their opinion on Clovis Oncology, Inc. (NASDAQ:CLVS), with 3 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation [T1].